CN101784542B - 咪唑酮衍生物、制备方法及生物用途 - Google Patents

咪唑酮衍生物、制备方法及生物用途 Download PDF

Info

Publication number
CN101784542B
CN101784542B CN200880103961.8A CN200880103961A CN101784542B CN 101784542 B CN101784542 B CN 101784542B CN 200880103961 A CN200880103961 A CN 200880103961A CN 101784542 B CN101784542 B CN 101784542B
Authority
CN
China
Prior art keywords
base
benzo dioxolane
group
reaction
benzo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200880103961.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN101784542A (zh
Inventor
F·卡罗
J-P·巴聚罗
S·雷诺
L·梅杰
O·洛扎赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Rennes 1
Original Assignee
Universite de Rennes 1
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Rennes 1 filed Critical Universite de Rennes 1
Publication of CN101784542A publication Critical patent/CN101784542A/zh
Application granted granted Critical
Publication of CN101784542B publication Critical patent/CN101784542B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN200880103961.8A 2007-08-01 2008-08-01 咪唑酮衍生物、制备方法及生物用途 Active CN101784542B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0705632 2007-08-01
FR0705632A FR2919608B1 (fr) 2007-08-01 2007-08-01 Derives d'imidazolones,procede de preparation et applications biologiques
PCT/FR2008/001152 WO2009050352A2 (fr) 2007-08-01 2008-08-01 Derives d'imidazolones, procede de preparation et applications biologiques

Publications (2)

Publication Number Publication Date
CN101784542A CN101784542A (zh) 2010-07-21
CN101784542B true CN101784542B (zh) 2014-04-02

Family

ID=39323606

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880103961.8A Active CN101784542B (zh) 2007-08-01 2008-08-01 咪唑酮衍生物、制备方法及生物用途

Country Status (12)

Country Link
US (1) US8563588B2 (enExample)
EP (1) EP2185547B1 (enExample)
JP (1) JP5926885B2 (enExample)
KR (1) KR20100051698A (enExample)
CN (1) CN101784542B (enExample)
BR (1) BRPI0814457A2 (enExample)
CA (1) CA2694377A1 (enExample)
ES (1) ES2644087T3 (enExample)
FR (1) FR2919608B1 (enExample)
MX (1) MX2010001170A (enExample)
RU (1) RU2491283C2 (enExample)
WO (1) WO2009050352A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102405212B (zh) * 2009-02-18 2016-01-27 康奈尔大学 在体内外使用的偶联识别/检测系统
EP2281824A1 (en) 2009-08-07 2011-02-09 Noscira, S.A. Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
US11453646B2 (en) 2011-07-27 2022-09-27 Cornell University Methods for RNA detection and quantification
CA2880487C (en) * 2012-07-30 2018-07-24 Kyoto University Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor
FR3002044A1 (fr) * 2013-02-08 2014-08-15 Centre Nat Rech Scient Marqueur dyrk1a pour la maladie d'alzheimer
EP3043646A4 (en) * 2013-08-29 2017-05-17 D. Tyler Mcquade Methods of making 2-halonicotinonitriles
US9664676B2 (en) 2013-09-06 2017-05-30 Cornell University RNA sequences that induce fluorescence of small molecule fluorophores
CN104370891B (zh) * 2014-10-17 2016-09-07 中国农业大学 一种5-(丁烯内酯-3-亚乙基)-2-氨基咪唑啉酮类化合物、制备方法及其应用
RU2730550C1 (ru) * 2019-05-15 2020-08-24 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Производное 2-селеноксо-тетрагидро-4н-имидазол-4-она, способ его получения и применения
WO2021114314A1 (en) * 2019-12-14 2021-06-17 Tongji University Novel heterocyclic derivatives with cardiomyocyte proliferation activity for treatment of heart diseases
WO2021114315A1 (en) * 2019-12-14 2021-06-17 Shanghai East Hospital Use of heterocyclic derivatives with cardiomyocyte proliferation activity for treatment of heart diseases
CN114945569A (zh) * 2019-12-26 2022-08-26 延世大学校产学协力团 吡咯烷衍生物，以及包含其的用于预防或治疗β-淀粉样蛋白或Tau蛋白相关疾病的药物组合物
KR20230005197A (ko) 2020-04-30 2023-01-09 페르하 파마슈티컬스 특정 dyrk1a, clk1 및/또는 clk4에서 단백질 키나제의 억제제로서의 신규한 이미다졸론 유도체
EP3904354A1 (en) 2020-04-30 2021-11-03 Perha Pharmaceuticals New imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4
EP4173674A1 (en) 2021-10-26 2023-05-03 Perha Pharmaceuticals Imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4
EP4173673A1 (en) 2021-10-26 2023-05-03 Perha Pharmaceuticals Imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4
EP4173675A1 (en) 2021-10-26 2023-05-03 Perha Pharmaceuticals Imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4
WO2025069008A1 (en) 2023-09-28 2025-04-03 Graviton Bioscience Bv Therapy for treating type 1 diabetes using rock2 and dyrk1 inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1038050B (de) * 1955-11-17 1958-09-04 Farmaceutici Italia S A Soc Verfahren zur Herstellung von 5-(3', 4'-Dioxybenzyliden)-Derivaten heterocyclischer Verbindungen
US4431656A (en) * 1981-02-05 1984-02-14 Kanegafuchi Chemical Industry Company Limited 3,5-di-Tert-butylstyrene derivatives, salts thereof, and pharmaceutical compositions containing the same as an active ingredient
GR79384B (enExample) * 1982-08-20 1984-10-22 Hoechst Uk Ltd
IE62214B1 (en) * 1988-05-25 1995-01-11 Warner Lambert Co Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents
DE69007413T2 (de) * 1989-10-09 1994-07-21 Toshiba Kawasaki Kk Organisches Material für die nichtlineare Optik und nichtlineare optische Vorrichtung.
US5143928A (en) * 1990-03-27 1992-09-01 Warner-Lambert Company 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
ATE146462T1 (de) * 1990-04-27 1997-01-15 Orion Yhtymae Oy Pharmakologisch aktive catecholderivate
JP3015702B2 (ja) * 1995-02-21 2000-03-06 株式会社アラクス イミダゾール誘導体及びそれらの薬剤として許容される酸付加塩及びその製造法並びにそれらを有効成分とする抗潰瘍剤
US6218437B1 (en) * 1996-09-30 2001-04-17 The Regents Of The University Of California Treatment and prevention of hepatic disorders
PL187019B1 (pl) * 1997-02-19 2004-04-30 Univ Jagiellonski Collegium Me Nowe związki, pochodne 5-arylideno-4-okso-2-imidazolidynoglicyny
EG21566A (en) * 1999-09-21 2001-12-31 Hosny Hamed Hoharam Synthesis of 5-(4-dimethylaminobenzli-dene)-2-phenylhydrozino (1,3-h) imidazole-4-one (iii)
WO2004052373A1 (en) * 2002-12-06 2004-06-24 Warner-Lambert Company Llc Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
FR2855755B1 (fr) * 2003-06-05 2007-09-07 Oreal Utilisation d'au moins un filtre de la lumiere bleue pour preserve le capital de carotenoides endogenes de la peau; nouveaux filtres de la lumiere bleue; compositions cosmetiques
ES2328146T3 (es) * 2003-07-28 2009-11-10 Merck Serono Sa 2-imino-4-(tio)oxo-5-policiclovinilazolinas para su uso como inhibidores de p13 quinasas.
JP2008516905A (ja) * 2004-10-14 2008-05-22 エフ．ホフマン−ラ ロシュ アーゲー Ｃｄｋ１抗増殖活性を有する１，５−ナフチリジンアゾリジノン
EP1868616A2 (en) * 2005-03-29 2007-12-26 The University of Maryland, Baltimore Inhibitors for extracellular signal-regulated kinase docking domains and uses therefor
US7304074B2 (en) * 2005-04-05 2007-12-04 Hoffmann-La Roche Inc. Substituted 1,5-naphthyridine azolinones
JP2007063444A (ja) * 2005-08-31 2007-03-15 Tdk Corp 錯化合物及びこれを用いた光記録媒体
US7371862B2 (en) * 2005-11-11 2008-05-13 Pfizer Italia S.R.L. Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2007065261A1 (en) * 2005-12-07 2007-06-14 American Diagnostica Inc. Plasminogen activator inhibitor-1 inhibitors

Also Published As

Publication number Publication date
FR2919608B1 (fr) 2012-10-05
EP2185547A2 (fr) 2010-05-19
RU2491283C2 (ru) 2013-08-27
MX2010001170A (es) 2010-06-25
EP2185547B1 (fr) 2017-07-19
ES2644087T3 (es) 2017-11-27
WO2009050352A3 (fr) 2009-07-23
KR20100051698A (ko) 2010-05-17
JP2010535180A (ja) 2010-11-18
FR2919608A1 (fr) 2009-02-06
US8563588B2 (en) 2013-10-22
WO2009050352A2 (fr) 2009-04-23
US20100216855A1 (en) 2010-08-26
CN101784542A (zh) 2010-07-21
BRPI0814457A2 (pt) 2015-01-06
RU2010107262A (ru) 2011-09-10
CA2694377A1 (fr) 2009-04-23
JP5926885B2 (ja) 2016-05-25

Similar Documents

Publication Publication Date Title
CN101784542B (zh) 咪唑酮衍生物、制备方法及生物用途
CA2762680C (en) Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics
EP1812439B2 (en) Kinase inhibitors
JP5103403B2 (ja) ２−ピリミジニルピラゾロピリジンＥｒｂＢキナーゼ阻害剤
EP2555768B1 (en) Ire-1 inhibitors
JP5790629B2 (ja) 二環式ヘテロアリール化合物からなるがん治療剤
EP1758857B1 (en) Indole derivatives as antiviral agents
JP6215832B2 (ja) アミノピリミジンキナーゼ阻害剤
CA3117200A1 (en) Tyk2 inhibitors and uses thereof
JP2019521082A (ja) Ｌｓｄ１／ｈｄａｃ二重阻害剤としてのシクロプロピル−アミド化合物
SK13332001A3 (sk) Inhibítory IMPDH enzýmu a ich použitie
MX2007010401A (es) Derivados de 2,4-diamino-piridopirimidina y su uso como inhbidores de mtor.
CN113429387B (zh) 一种苯并[b]硒吩类STING调控剂、其制备方法及用途
TW201831453A (zh) 四取代烯化合物及其用途
KR20100014720A (ko) 단백질 키나아제의 조절제로서 (ｓ)-2-아미노-1-(4-클로로페닐)-1-[4-(1ｈ-피라졸-4-일)-페닐]-에탄올을 포함하는 조성물
CN1495182A (zh) 用于抑制细胞增殖的取代的双吲哚基马来酰亚胺
CN107043366B (zh) 4-氨基嘧啶类化合物、其制备方法及医药用途
KR20200055126A (ko) Ａ2ａ수용체 억제제로서의 축합 고리 유도체
WO2015110092A1 (zh) 4-取代吡咯并[2,3-d]嘧啶化合物及其用途
CN119451948A (zh) 作为trpa1抑制剂的吡啶酮化合物
CN117447460A (zh) 作为ripk1抑制剂的杂环化合物
WO2021129629A1 (zh) Zeste增强子同源物2抑制剂及其用途
WO2001005789A1 (en) TRICYCLIC COMPOUNDS HAVING sPLA2-INHIBITORY ACTIVITIES
CN118812445A (zh) 苯磺酰胺类wdr5-myc相互作用抑制剂及其药物组合物和用途
CN115232030A (zh) 芳基脲类化合物及其制法和药物用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant